Concepts (259)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urology | 10 | 2023 | 110 | 5.800 |
Why?
|
| Prostatic Neoplasms | 22 | 2023 | 1721 | 4.190 |
Why?
|
| Medicare | 19 | 2023 | 410 | 3.710 |
Why?
|
| Drug Industry | 4 | 2023 | 54 | 2.590 |
Why?
|
| Accountable Care Organizations | 5 | 2022 | 13 | 2.500 |
Why?
|
| Urologists | 5 | 2023 | 24 | 2.400 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2024 | 383 | 2.030 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2021 | 582 | 2.030 |
Why?
|
| Prostatectomy | 9 | 2023 | 471 | 2.010 |
Why?
|
| Prostate-Specific Antigen | 9 | 2022 | 353 | 2.000 |
Why?
|
| Prostatic Hyperplasia | 3 | 2023 | 88 | 1.790 |
Why?
|
| United States | 31 | 2023 | 6672 | 1.580 |
Why?
|
| Prostate | 5 | 2022 | 378 | 1.550 |
Why?
|
| Urologic Diseases | 2 | 2023 | 45 | 1.520 |
Why?
|
| Cost Savings | 5 | 2022 | 66 | 1.310 |
Why?
|
| Physicians | 3 | 2023 | 673 | 1.170 |
Why?
|
| Erectile Dysfunction | 3 | 2023 | 74 | 1.130 |
Why?
|
| Kidney Neoplasms | 6 | 2021 | 621 | 1.070 |
Why?
|
| Male | 46 | 2023 | 40965 | 1.030 |
Why?
|
| Lymph Node Excision | 5 | 2019 | 217 | 1.020 |
Why?
|
| Aged | 32 | 2024 | 18415 | 1.000 |
Why?
|
| Aortic Valve Stenosis | 3 | 2021 | 131 | 0.980 |
Why?
|
| Humans | 63 | 2024 | 86643 | 0.980 |
Why?
|
| Pyrimidinones | 1 | 2023 | 36 | 0.940 |
Why?
|
| Circumcision, Male | 1 | 2023 | 18 | 0.940 |
Why?
|
| Penile Induration | 1 | 2023 | 6 | 0.920 |
Why?
|
| Transcatheter Aortic Valve Replacement | 2 | 2021 | 47 | 0.890 |
Why?
|
| Cystectomy | 3 | 2024 | 102 | 0.860 |
Why?
|
| Health Care Sector | 1 | 2021 | 13 | 0.830 |
Why?
|
| Angiomyolipoma | 1 | 2021 | 15 | 0.830 |
Why?
|
| Equipment and Supplies | 1 | 2021 | 30 | 0.820 |
Why?
|
| Conflict of Interest | 1 | 2021 | 67 | 0.800 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2019 | 166 | 0.780 |
Why?
|
| Health Expenditures | 2 | 2020 | 86 | 0.770 |
Why?
|
| Biomedical Technology | 1 | 2020 | 20 | 0.760 |
Why?
|
| Publishing | 1 | 2021 | 90 | 0.760 |
Why?
|
| Drug Prescriptions | 2 | 2019 | 141 | 0.740 |
Why?
|
| Health Policy | 2 | 2020 | 180 | 0.740 |
Why?
|
| Episode of Care | 1 | 2019 | 7 | 0.730 |
Why?
|
| Robotic Surgical Procedures | 5 | 2022 | 267 | 0.730 |
Why?
|
| Carcinoma, Renal Cell | 6 | 2020 | 426 | 0.710 |
Why?
|
| Conservative Treatment | 1 | 2019 | 20 | 0.710 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2019 | 59 | 0.700 |
Why?
|
| Meniscectomy | 1 | 2018 | 3 | 0.680 |
Why?
|
| Vertebroplasty | 1 | 2018 | 8 | 0.680 |
Why?
|
| Reimbursement Mechanisms | 1 | 2019 | 41 | 0.670 |
Why?
|
| Office Visits | 1 | 2019 | 44 | 0.670 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 182 | 0.650 |
Why?
|
| Urological Agents | 1 | 2018 | 5 | 0.650 |
Why?
|
| Ureteral Calculi | 1 | 2017 | 10 | 0.630 |
Why?
|
| Health Care Costs | 1 | 2019 | 238 | 0.620 |
Why?
|
| Aftercare | 1 | 2018 | 85 | 0.600 |
Why?
|
| Hospitals, Pediatric | 1 | 2017 | 106 | 0.580 |
Why?
|
| Aged, 80 and over | 11 | 2021 | 6509 | 0.570 |
Why?
|
| Patient Participation | 1 | 2018 | 216 | 0.560 |
Why?
|
| Databases, Factual | 4 | 2023 | 814 | 0.550 |
Why?
|
| Pneumoperitoneum | 1 | 2015 | 4 | 0.540 |
Why?
|
| Retrospective Studies | 14 | 2023 | 8489 | 0.540 |
Why?
|
| Telemedicine | 1 | 2018 | 169 | 0.530 |
Why?
|
| Quality of Health Care | 1 | 2018 | 380 | 0.520 |
Why?
|
| Treatment Outcome | 13 | 2022 | 7993 | 0.510 |
Why?
|
| Kidney Calculi | 1 | 2017 | 339 | 0.480 |
Why?
|
| Hospitalization | 1 | 2017 | 849 | 0.410 |
Why?
|
| Group Practice | 2 | 2021 | 7 | 0.400 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 938 | 0.390 |
Why?
|
| Lymph Nodes | 3 | 2020 | 533 | 0.380 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 3362 | 0.350 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 426 | 0.330 |
Why?
|
| Registries | 3 | 2023 | 702 | 0.330 |
Why?
|
| Middle Aged | 18 | 2021 | 25028 | 0.320 |
Why?
|
| Neoplasms | 1 | 2022 | 2898 | 0.300 |
Why?
|
| Female | 16 | 2021 | 44532 | 0.280 |
Why?
|
| Pelvis | 2 | 2017 | 95 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2022 | 1313 | 0.250 |
Why?
|
| Neoplasm Invasiveness | 2 | 2024 | 552 | 0.250 |
Why?
|
| Lymphatic Metastasis | 4 | 2019 | 486 | 0.240 |
Why?
|
| Industry | 1 | 2023 | 16 | 0.230 |
Why?
|
| Men's Health | 1 | 2023 | 6 | 0.230 |
Why?
|
| Pyrrolidines | 1 | 2023 | 58 | 0.230 |
Why?
|
| Hematuria | 1 | 2023 | 49 | 0.220 |
Why?
|
| Cryotherapy | 1 | 2022 | 29 | 0.220 |
Why?
|
| Phenylthiohydantoin | 2 | 2020 | 41 | 0.220 |
Why?
|
| Insurance Carriers | 1 | 2022 | 6 | 0.220 |
Why?
|
| Androstenes | 2 | 2020 | 43 | 0.220 |
Why?
|
| Linear Models | 1 | 2023 | 421 | 0.220 |
Why?
|
| Patient Care | 1 | 2023 | 100 | 0.210 |
Why?
|
| Medicare Part D | 2 | 2020 | 10 | 0.210 |
Why?
|
| Seminal Vesicles | 1 | 2022 | 39 | 0.210 |
Why?
|
| Financial Statements | 1 | 2021 | 3 | 0.210 |
Why?
|
| Adipose Tissue | 2 | 2015 | 240 | 0.210 |
Why?
|
| Urinary Bladder | 1 | 2024 | 246 | 0.210 |
Why?
|
| Professional Misconduct | 1 | 2021 | 25 | 0.210 |
Why?
|
| Neoplasm Grading | 1 | 2023 | 357 | 0.200 |
Why?
|
| Combined Modality Therapy | 3 | 2024 | 1686 | 0.200 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 92 | 0.200 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2021 | 59 | 0.200 |
Why?
|
| Image-Guided Biopsy | 1 | 2021 | 66 | 0.190 |
Why?
|
| Disclosure | 1 | 2021 | 108 | 0.190 |
Why?
|
| Peritoneal Neoplasms | 1 | 2022 | 177 | 0.190 |
Why?
|
| Inpatients | 1 | 2023 | 297 | 0.190 |
Why?
|
| Neoplasm Staging | 7 | 2020 | 1939 | 0.190 |
Why?
|
| Reimbursement, Incentive | 1 | 2020 | 37 | 0.180 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2020 | 237 | 0.180 |
Why?
|
| Adult | 9 | 2023 | 25648 | 0.180 |
Why?
|
| Seminoma | 1 | 2019 | 10 | 0.180 |
Why?
|
| Cohort Studies | 4 | 2022 | 2767 | 0.180 |
Why?
|
| Retroperitoneal Space | 1 | 2019 | 38 | 0.180 |
Why?
|
| Dementia | 1 | 2021 | 187 | 0.180 |
Why?
|
| Child | 2 | 2023 | 6927 | 0.180 |
Why?
|
| Ureteroscopes | 1 | 2019 | 3 | 0.170 |
Why?
|
| Cost Control | 1 | 2019 | 44 | 0.170 |
Why?
|
| Disposable Equipment | 1 | 2019 | 18 | 0.170 |
Why?
|
| Medication Adherence | 1 | 2020 | 129 | 0.170 |
Why?
|
| Hematologic Tests | 1 | 2018 | 14 | 0.170 |
Why?
|
| Health Care Surveys | 1 | 2019 | 278 | 0.170 |
Why?
|
| Time Factors | 4 | 2021 | 5210 | 0.160 |
Why?
|
| Solifenacin Succinate | 1 | 2018 | 6 | 0.160 |
Why?
|
| Michigan | 1 | 2018 | 52 | 0.160 |
Why?
|
| Testicular Neoplasms | 1 | 2019 | 105 | 0.160 |
Why?
|
| Acetanilides | 1 | 2018 | 6 | 0.160 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2018 | 35 | 0.160 |
Why?
|
| Early Detection of Cancer | 2 | 2020 | 394 | 0.160 |
Why?
|
| Wearable Electronic Devices | 1 | 2018 | 23 | 0.160 |
Why?
|
| Biopsy | 1 | 2022 | 1163 | 0.160 |
Why?
|
| Benzhydryl Compounds | 1 | 2018 | 48 | 0.160 |
Why?
|
| Databases as Topic | 1 | 2018 | 92 | 0.160 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 203 | 0.160 |
Why?
|
| Watchful Waiting | 1 | 2018 | 60 | 0.160 |
Why?
|
| Infant, Newborn | 1 | 2023 | 2379 | 0.160 |
Why?
|
| Cardiac Catheterization | 1 | 2019 | 291 | 0.150 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2019 | 111 | 0.150 |
Why?
|
| Alzheimer Disease | 1 | 2021 | 470 | 0.150 |
Why?
|
| Urinary Calculi | 1 | 2017 | 46 | 0.150 |
Why?
|
| Thiazoles | 1 | 2018 | 131 | 0.150 |
Why?
|
| Health Status | 1 | 2019 | 360 | 0.150 |
Why?
|
| Incidence | 3 | 2017 | 1577 | 0.150 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 1621 | 0.150 |
Why?
|
| Risk | 1 | 2019 | 674 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 454 | 0.150 |
Why?
|
| Disease Management | 1 | 2019 | 327 | 0.150 |
Why?
|
| Sildenafil Citrate | 1 | 2016 | 22 | 0.150 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2016 | 9 | 0.150 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2018 | 87 | 0.150 |
Why?
|
| Prognosis | 4 | 2017 | 3679 | 0.150 |
Why?
|
| Surgeons | 1 | 2021 | 238 | 0.140 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 2360 | 0.140 |
Why?
|
| Carboxymethylcellulose Sodium | 1 | 2016 | 7 | 0.140 |
Why?
|
| Patient Readmission | 1 | 2020 | 329 | 0.140 |
Why?
|
| Indoles | 1 | 2018 | 318 | 0.140 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 567 | 0.140 |
Why?
|
| Hyaluronic Acid | 1 | 2016 | 49 | 0.140 |
Why?
|
| Risk Assessment | 2 | 2017 | 2261 | 0.140 |
Why?
|
| Urologic Surgical Procedures | 1 | 2017 | 146 | 0.140 |
Why?
|
| Mass Screening | 1 | 2020 | 618 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2020 | 860 | 0.130 |
Why?
|
| Insufflation | 1 | 2015 | 10 | 0.130 |
Why?
|
| Referral and Consultation | 1 | 2018 | 328 | 0.130 |
Why?
|
| Hospital Charges | 1 | 2015 | 29 | 0.130 |
Why?
|
| RNA, Neoplasm | 1 | 2015 | 87 | 0.130 |
Why?
|
| Operative Time | 1 | 2015 | 127 | 0.130 |
Why?
|
| Hemoglobins | 1 | 2015 | 179 | 0.130 |
Why?
|
| Pressure | 1 | 2015 | 165 | 0.130 |
Why?
|
| Interleukin-2 | 1 | 2015 | 249 | 0.130 |
Why?
|
| Receptors, Androgen | 1 | 2015 | 113 | 0.120 |
Why?
|
| Sex Factors | 1 | 2017 | 1054 | 0.120 |
Why?
|
| Neutrophils | 1 | 2015 | 307 | 0.120 |
Why?
|
| Logistic Models | 1 | 2017 | 1186 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 1 | 2015 | 384 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 1991 | 0.120 |
Why?
|
| Adolescent | 4 | 2022 | 8981 | 0.110 |
Why?
|
| Quality of Life | 1 | 2021 | 1585 | 0.110 |
Why?
|
| Patient Safety | 1 | 2015 | 212 | 0.110 |
Why?
|
| Age Factors | 1 | 2017 | 1851 | 0.110 |
Why?
|
| Postoperative Complications | 2 | 2020 | 2207 | 0.100 |
Why?
|
| Digital Rectal Examination | 1 | 2010 | 7 | 0.100 |
Why?
|
| Ureteral Diseases | 1 | 2010 | 14 | 0.100 |
Why?
|
| Child, Preschool | 1 | 2017 | 3612 | 0.090 |
Why?
|
| Kidney | 1 | 2016 | 1241 | 0.090 |
Why?
|
| Algorithms | 1 | 2018 | 1830 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 1197 | 0.090 |
Why?
|
| Nitriles | 2 | 2020 | 149 | 0.090 |
Why?
|
| Catheterization | 1 | 2010 | 232 | 0.090 |
Why?
|
| Coronary Artery Bypass | 2 | 2021 | 228 | 0.090 |
Why?
|
| Benzamides | 2 | 2020 | 229 | 0.080 |
Why?
|
| Survival Rate | 3 | 2020 | 1863 | 0.080 |
Why?
|
| Prosthesis-Related Infections | 1 | 2008 | 58 | 0.080 |
Why?
|
| Kallikreins | 2 | 2020 | 47 | 0.080 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2008 | 87 | 0.080 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2008 | 112 | 0.080 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2008 | 228 | 0.070 |
Why?
|
| Penile Erection | 2 | 2016 | 22 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 3640 | 0.070 |
Why?
|
| Kidney Transplantation | 1 | 2010 | 849 | 0.060 |
Why?
|
| Capecitabine | 1 | 2024 | 96 | 0.060 |
Why?
|
| Young Adult | 4 | 2019 | 5976 | 0.060 |
Why?
|
| Gallium Isotopes | 1 | 2022 | 2 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 1204 | 0.050 |
Why?
|
| Gallium Radioisotopes | 1 | 2022 | 32 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 2357 | 0.050 |
Why?
|
| Perineum | 1 | 2021 | 35 | 0.050 |
Why?
|
| Cisplatin | 1 | 2024 | 612 | 0.050 |
Why?
|
| Ultrasonography, Interventional | 1 | 2021 | 121 | 0.050 |
Why?
|
| Fee-for-Service Plans | 1 | 2021 | 30 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2021 | 4213 | 0.050 |
Why?
|
| Income | 1 | 2020 | 75 | 0.050 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 166 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2021 | 596 | 0.050 |
Why?
|
| Hospitals | 1 | 2022 | 294 | 0.050 |
Why?
|
| SEER Program | 1 | 2020 | 190 | 0.050 |
Why?
|
| Colectomy | 1 | 2021 | 167 | 0.050 |
Why?
|
| Drug Costs | 1 | 2020 | 62 | 0.050 |
Why?
|
| Orchiectomy | 1 | 2019 | 68 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2020 | 307 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2020 | 117 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2020 | 364 | 0.040 |
Why?
|
| Testis | 1 | 2019 | 152 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2020 | 684 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2015 | 1538 | 0.040 |
Why?
|
| Propensity Score | 1 | 2018 | 136 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2019 | 238 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 859 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2020 | 294 | 0.040 |
Why?
|
| Trauma, Nervous System | 1 | 2016 | 6 | 0.040 |
Why?
|
| Length of Stay | 1 | 2020 | 702 | 0.040 |
Why?
|
| Cyclic GMP | 1 | 2016 | 58 | 0.040 |
Why?
|
| Medicaid | 1 | 2019 | 217 | 0.040 |
Why?
|
| Penis | 1 | 2016 | 57 | 0.040 |
Why?
|
| Nitric Oxide Synthase | 1 | 2016 | 125 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 2016 | 158 | 0.030 |
Why?
|
| Taiwan | 1 | 2015 | 23 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2015 | 31 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2016 | 180 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2015 | 94 | 0.030 |
Why?
|
| Internationality | 1 | 2015 | 69 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2016 | 303 | 0.030 |
Why?
|
| Muscle, Smooth | 1 | 2016 | 354 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 273 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2016 | 1219 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 782 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 999 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2705 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2013 | 292 | 0.030 |
Why?
|
| Risk Factors | 2 | 2015 | 5417 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2013 | 233 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 468 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1961 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 1056 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 59 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 1531 | 0.020 |
Why?
|
| Rats | 1 | 2016 | 3990 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2010 | 213 | 0.020 |
Why?
|
| Ureter | 1 | 2010 | 92 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 2426 | 0.020 |
Why?
|
| Laparoscopy | 1 | 2016 | 754 | 0.020 |
Why?
|
| Illinois | 1 | 2008 | 462 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 1128 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 1464 | 0.020 |
Why?
|
| Comorbidity | 1 | 2008 | 943 | 0.020 |
Why?
|
| Animals | 1 | 2016 | 26582 | 0.010 |
Why?
|